Subtype Classification and Prognosis Signature Construction of Osteosarcoma Based on Cellular Senescence-Related Genes

被引:6
作者
Wang, Hanyu [1 ]
Liu, Hongliang [2 ]
Wang, Li [1 ]
Xu, Shuchai [2 ]
Pi, Honglin [1 ]
Cheng, Zhian [2 ]
机构
[1] Hubei Univ Chinese Med, Xiangyang Hosp Tradit Chinese Med, Dept Orthoped, Xiangyang 441002, Hubei, Peoples R China
[2] Guangzhou Univ Chinese Med, Guangdong Hosp Chinese Med, Clin Med Coll 2, Dept Orthoped, Guangzhou 510000, Guangdong, Peoples R China
关键词
MULTIDRUG-RESISTANCE; EXPRESSION; DATABASE; CANCER; STAGE; DLX2;
D O I
10.1155/2022/4421952
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Cellular senescence (CS) is an alternative procedure that replaces or reinforces inadequate apoptotic responses and is used as an influencing factor for a variety of cancers. The value of CS gene in evaluating the immunotherapy response and clinical outcome of osteosarcoma (OS) has not been reported, and an accurate risk model based on CS gene has not been developed for OS patients. Methods. 279 CS genes were obtained from CellAge. Univariate Cox regression analysis was used to screen the CS gene which was significantly related to the prognosis of OS samples in TARGET data set. The prognosis, clinicopathological features, immune infiltration, gene expression at immune checkpoints, tumor immune dysfunction and exclusion (TIDE) score, and chemotherapy resistance of OS were analyzed among clusters. Least absolute shrinkage and selection operator (Lasso) Cox regression analysis to build cellular senescence-related gene signature (CSRS). Univariate and multivariate Cox regression analysis of CSRS and clinical parameters were carried out, and the parameters with independent prognostic value were used to construct nomogram. Results. Based on 30 CS genes related to OS prognosis, OS samples were divided into three clusters: C1, C2, and C3. C3 showed the lowest survival rate and metastasis rate and the highest immune score and stromal score and was more likely to respond to immune checkpoint blockade (ICB) treatment. A CSRS scoring system including four CS genes (MYC, DLX2, EPHA3, and LIMK1) was constructed, which could distinguish the survival outcome, tumor microenvironment (TME) status, and ICB treatment response of patients with different CSRS score. Nomogram constructed by CSRS score and metastatic has a high prognostic value for OS. Conclusions. Our study identified a molecular classification determined by CS-related genes and developed a new CSRS that has potential value in OS immunotherapy response and clinical outcome prediction.
引用
收藏
页数:15
相关论文
共 39 条
  • [11] RETRACTED: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma (Retracted article. See vol. 15, 2023)
    Feng, Wenlong
    Dean, Dylan C.
    Hornicek, Francis J.
    Spentzos, Dimitrios
    Hoffman, Robert M.
    Shi, Huirong
    Duan, Zhenfeng
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [12] pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
    Geeleher, Paul
    Cox, Nancy
    Huang, R. Stephanie
    [J]. PLOS ONE, 2014, 9 (09):
  • [13] A guide to assessing cellular senescencein vitroandin vivo
    Gonzalez-Gualda, Estela
    Baker, Andrew G.
    Fruk, Ljiljana
    Munoz-Espin, Daniel
    [J]. FEBS JOURNAL, 2021, 288 (01) : 56 - 80
  • [14] Cellular Senescence: Defining a Path Forward
    Gorgoulis, Vassilis
    Adams, Peter D.
    Alimonti, Andrea
    Bennett, Dorothy C.
    Bischof, Oliver
    Bishop, Cleo
    Campisi, Judith
    Collado, Manuel
    Evangelou, Konstantinos
    Ferbeyre, Gerardo
    Gil, Jesus
    Hara, Eiji
    Krizhanovsky, Valery
    Jurk, Diana
    Maier, Andrea B.
    Narita, Masashi
    Niedernhofer, Laura
    Passos, Joao F.
    Robbins, Paul D.
    Schmitt, Clemens A.
    Sedivy, John
    Vougas, Konstantinos
    von Zglinicki, Thomas
    Zhou, Daohong
    Serrano, Manuel
    Demaria, Marco
    [J]. CELL, 2019, 179 (04) : 813 - 827
  • [15] Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
    Harris, Michael A.
    Hawkins, Christine J.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [16] Trends in Tumor Site-Specific Survival of Bone Sarcomas from 1980 to 2018: A Surveillance, Epidemiology and End Results-Based Study
    Hu, Xianglin
    Deng, Kai
    Ye, Hui
    Sun, Zhengwang
    Huang, Wending
    Sun, Yangbai
    Yan, Wangjun
    [J]. CANCERS, 2021, 13 (21)
  • [17] MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma
    Jiang, Kuo
    Zhang, Qianfeng
    Fan, Yong
    Li, Jia
    Zhang, Jitao
    Wang, Wentao
    Fan, Jinzhu
    Guo, Yunshan
    Liu, Shichang
    Hao, Dingjun
    Wang, Yongxiang
    Wang, Lei
    Shan, Lequn
    [J]. CELL DEATH DISCOVERY, 2022, 8 (01)
  • [18] Cellular senescence bypass screen identifies new putative tumor suppressor genes
    Leal, J. F. M.
    Fominaya, J.
    Cascon, A.
    Guijarro, M. V.
    Blanco-Aparicio, C.
    Lleonart, M.
    Castro, M. E.
    Ramon y Cajal, S.
    Robledo, M.
    Beach, D. H.
    Carnero, A.
    [J]. ONCOGENE, 2008, 27 (14) : 1961 - 1970
  • [19] The Molecular Signatures Database Hallmark Gene Set Collection
    Liberzon, Arthur
    Birger, Chet
    Thorvaldsdottir, Helga
    Ghandi, Mahmoud
    Mesirov, Jill P.
    Tamayo, Pablo
    [J]. CELL SYSTEMS, 2015, 1 (06) : 417 - 425
  • [20] Comprehensive Analysis Uncovers Prognostic and Immunogenic Characteristics of Cellular Senescence for Lung Adenocarcinoma
    Lin, Weihao
    Wang, Xin
    Wang, Zhen
    Shao, Fei
    Yang, Yannan
    Cao, Zheng
    Feng, Xiaoli
    Gao, Yibo
    He, Jie
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9